Antonella Bacchiocchi
Research Associate DermatologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Research Associate Dermatology
Departments & Organizations
- All Institutions
- Halaban Lab
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonella Bacchiocchi's published research.
Publications Timeline
A big-picture view of Antonella Bacchiocchi's research output by year.
Ruth Halaban, PhD
Mario Sznol, MD
Harriet Kluger, MD
David F. Stern, PhD
Stephan Ariyan, MD, MBA
Douglas E Brash, PhD
52Publications
5,052Citations
Publications
2026
Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies
Lahav C, Dahan N, Harel M, Elon Y, Sela I, Geyer P, Schneider M, Muley T, Bacchiocchi A, Marte J, Floudas C, Halaban R, Sznol M, Christopoulos P, Gulley J. Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies. Journal Of Pharmaceutical And Biomedical Analysis 2026, 274: 117421. PMID: 41713118, PMCID: PMC13008497, DOI: 10.1016/j.jpba.2026.117421.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsClonal determinants of organotropism and survival in metastatic uveal melanoma
Jones B, Hammes E, Demkowicz P, Matesva M, Pointdujour-Lim R, Sinard J, Bacchiocchi A, Halaban R, Bosenberg M, Sznol M, Kluger H, Bakhoum M. Clonal determinants of organotropism and survival in metastatic uveal melanoma. Npj Precision Oncology 2026, 10: 68. PMID: 41582235, PMCID: PMC12913882, DOI: 10.1038/s41698-026-01274-8.Peer-Reviewed Original ResearchAltmetricConceptsUveal melanomaLiver metastasesClonality determinationPost-metastatic survivalMetastatic uveal melanomaPatterns of disseminationBAP1 lossExtrahepatic metastasesPrimary tumorIntraocular cancerMetastatic spreadMetastasisMolecular profilingPatient outcomesMelanomaLiverSurvivalIntraocularMonosomyTumorBAP1PatientsCancerOrganotropism
2025
CTLA-4 blockade shifts the B cell repertoire towards autoimmunity
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas C, Bouis D, Boeckers J, Gera R, Yraita S, Clapp L, Perdigoto A, Delmotte F, Massad C, Bacchiocchi A, Ring A, Kluger Y, Kluger H, Herold K, Meffre E. CTLA-4 blockade shifts the B cell repertoire towards autoimmunity. Journal Of Clinical Investigation 2025, 135: e189074. PMID: 41026527, PMCID: PMC12618075, DOI: 10.1172/jci189074.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune-related adverse eventsAnti-PD-1CTLA-4 blockadeMature naive B cellsCTLA-4Naive B cellsB cell repertoireB cellsCheckpoint inhibitorsPD-1Emergence of immune-related adverse eventsAnti-CTLA-4 combination therapyCancer patientsReactivity of recombinant antibodiesCentral B cell tolerancePeripheral B cell repertoireAnti-CTLA-4B cell frequenciesBlood of cancer patientsAutoreactive B cellsB cell toleranceTreatment of cancer patientsSingle B cellsAntitumor responseCombination therapy1680P A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma
Sullivan R, Elon Y, Brody Y, Harel M, Dahan N, Shoval S, Boland G, Lawless A, Puzanov I, Danlos F, Marabelle A, Robert C, Shapira-Frommer R, Bacchiocchi A, Halaban R, Sznol M, Dicker A. 1680P A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma. Annals Of Oncology 2025, 36: s993-s994. DOI: 10.1016/j.annonc.2025.08.2308.Peer-Reviewed Original ResearchLZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis
Bacchiocchi A, Mak M, Khan Z, Gong X, Sznol M, Na Z, Su H, Chan L, Yan Q, Zhao D, Mortlock R, Knight J, Slavoff S, Halaban R. LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis. Oncogene 2025, 44: 3974-3984. PMID: 40885854, PMCID: PMC12500468, DOI: 10.1038/s41388-025-03538-2.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDegradation of ubiquitinated proteinsActin-related proteinsActin cytoskeleton organizationUbiquitin-proteasome systemSrc tyrosine kinaseAnchorage-independent growthNormal cell survivalCargo adapterActin organizationProximity biotinylationCytoskeleton organizationLC-MS/MS proteomicsLeucine zipperProteasome systemUbiquitinated proteinsCo-ImmunoprecipitationTargeting Pyk2Cell spreadingMelanoma cellsEnvironmental stressGrowth advantageMolecular characterizationCell migrationCell survivalLZTR1The ERVK3‑1 Microprotein Interacts with the HUSH Complex
Jayatissa A, Jaunbocus N, Erkalo B, Jiang K, Zheng S, Su H, Yan L, Choi J, Vaughan J, Bacchiocchi A, Na Z, Cao X, Halaban R, Saghatelian A, Craft J, Chen Y, Slavoff S. The ERVK3‑1 Microprotein Interacts with the HUSH Complex. Biochemistry 2025, 64: 3372-3381. PMID: 40699144, PMCID: PMC12339190, DOI: 10.1021/acs.biochem.5c00023.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsHUSH complexTranscriptional repressionHuman endogenous retrovirusesIntron-less geneRegulation of target gene expressionEndogenous retrovirusesTarget gene expressionGenomic elementsHuman genomeTarget genesGene expressionHuman cellsMicroproteinsExogenous retrovirusesLociGenesRetrovirusesRetrotransposonsGenomeMolecular remnantsRepressionPPHLN1ComplexRegulationBlocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors
Srivastava J, Yadav V, Jimenez R, Phadatare P, Inamdar N, Young M, Bacchiocchi A, Halaban R, Fang B, de Mingo Pulido A, Tsai K, Smalley K, Koomen J, Rodriguez P, Premi S. Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Research 2025, 85: 2268-2287. PMID: 40287947, PMCID: PMC12167936, DOI: 10.1158/0008-5472.can-24-0693.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsInduce immunogenic cell deathNRAS-mutant melanomaDamage-associated molecular patternsImmunogenic cell deathMEK inhibitorsDendritic cellsRepertoire of CD8+ T cellsCocultures of dendritic cellsCD8+ T cellsCell deathActivating NRAS mutationsAntimelanoma immune responsesImmunocompetent mouse modelInnovative treatment strategiesMEK-ERK signalingAntitumor immunityNRAS mutationsMelanoma subtypesERK MAPK pathwayTargeted therapyTumor microenvironmentT cellsT lymphocytesMelanoma growthTherapeutic resistanceFAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Lubrano S, Cervantes-Villagrana R, Faraji F, Ramirez S, Sato K, Adame-Garcia S, Officer A, Arang N, Rigiracciolo D, Anguiano Quiroz P, Martini C, Wang Y, Ferguson F, Bacchiocchi A, Halaban R, Coma S, Holmen S, Pachter J, Aplin A, Gutkind J. FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell 2025, 43: 428-445.e6. PMID: 40020669, PMCID: PMC11903146, DOI: 10.1016/j.ccell.2025.02.001.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBRAF V600E melanomaFocal adhesion kinaseV600E melanomaFAK inhibitorActivated focal adhesion kinaseFocal adhesion kinase inhibitionRaf-MEKActivation of focal adhesion signalingFocal adhesion kinase inhibitorResistance to BRAFiSyngeneic mouse modelMAPK pathway inhibitionFocal adhesion signalingPro-apoptotic activityMelanoma patientsAdhesion signalingImmune therapyBRAF mutationsBRAFiTranscriptome analysisMelanomaMouse modelPathway inhibitionBRAFMelanoma cells
2024
Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma
Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S, Rayon-Estrada V, Axisa P, Reeves S, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair F, Kluger H, Hafler D. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nature Immunology 2024, 26: 82-91. PMID: 39609626, PMCID: PMC12285569, DOI: 10.1038/s41590-024-02023-4.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCD8+ T cellsAnti-tumor immunityRegulatory T cellsT cellsSubpopulation of CD8+ T cellsCytotoxic CD8+ T cellsHuman CD8+ T cellsTumor antigen-specific CD8Impaired anti-tumor immunityTumor antigen-specificPoor overall survivalTumor rejectionKIR expressionOverall survivalTumor antigensImmune evasionCellular mediatorsHuman cancersCD8MelanomaTumorTranscriptional programsFunctional heterogeneityImmunityPatientsUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.Peer-Reviewed Original ResearchCitationsConceptsMolecular residual diseaseCirculating tumor DNAWhole-genome sequencingCell-free DNAGenome sequenceDetection of molecular residual diseaseCirculating tumor DNA detectionResidual disease detectionConsistent with clinical outcomesVariant allele frequencyResidual diseaseMelanoma patientsMonitoring immunotherapyTumor DNAEsophageal cancerClinical outcomesColorectal cancerWGS technologiesAllele frequenciesCancerDNAAnalytical sensitivitySequenceImmunotherapyRelapse
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link